StockMarketWire.com - Molecular diagnostics group Yourgene Health booked a first-half loss, though revenue improved as it continued to grow its customer base

Pre-tax losses for the six months through September amounted to £3.5m, narrowing from a £4.9m loss on-year.

Revenue rose 45% to £3.9m.

'We are making excellent commercial progress, with revenues and test volumes up by 45% and 73% respectively in the first half, with costs and cash consumption reducing rapidly,' chief executive Lyn Rees said.

'We continued to grow our customer base successfully outside of the IP-restricted markets for non-invasive prenatal testing in the period, and now have product and service sales in over 20 global territories.'

'With market access now clear post the settlement with Illumina, we will look to broaden our international reach with a refreshed and upskilled commercial structure.'


At 2:57pm: [LON:YGEN] share price was -0.5p at 8.25p



Story provided by StockMarketWire.com